Lexicon Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Lexicon Pharmaceuticals Inc.
Former names: Lexicon Genetics Inc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: The Woodlands
Headquarters state / province: Texas
Headquarters country: United States
Fiscal year end: December
Ticker symbol: LXRX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001062822
EIN: 76-0474169
Wikidata ID: Q6537727

Board of directors

Follow this board

Administratiekantoor Westend Stichting · Director
Since 2023
Alan S. Nies · Director
Since 2023
Amaury Wittouck · Director
Since 2023
Christopher J. Sobecki · Director
Since 2023
Diane E. Sullivan · Director
Since 2023
Frank Palantoni · Director
Since 2023
International S.c.a. Artal · Director
Since 2023
Ivan Cheung · Director
Since 2024
Judith L. Swain · Director
Since 2023
Lonnel Coats · Director · Chief Executive Officer
Since 2023
Michael Exton · Director · Chief Executive Officer
Since 2024
Participations S.a R.l. Artal · Director
Since 2024
Philippe Amouyal · Director
Since 2023
Raymond Debbane · Director
Since 2023
Robert J. Lefkowitz M.D. · Director
Since 2023
S.a. Westend · Director
Since 2023
Sam L. Barker · Director
Since 2023

Chief executives

Michael Exton · Chief Executive Officer

Since July 2024

100 CEO score

Outstanding · grade A+

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 20% of the scoring weight is on file.

Revenue growth 20%: 100

20% of the scoring weight is on file. Figures cover December 2023 – December 2025.

Lonnel Coats · Chief Executive Officer

Until July 2024 · Former

Director election results

Annual meeting of April 30, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

11 of this board's directors also sit on 6 other boards. 3 are in the same sector.

Shared director Other board Same sector

CAVA Group Inc.
via Administratiekantoor Westend Stichting, Amaury Wittouck, International S.c.a. Artal, Participations S.a R.l. Artal, Philippe Amouyal and S.a. Westend
WW International Inc.
via Christopher J. Sobecki and Raymond Debbane
Amarin Corporation plc Same sector
via Diane E. Sullivan
Bio Green Med Solution Inc.
via Sam L. Barker
Mineralys Therapeutics Inc. Same sector
via Lonnel Coats
Relay Therapeutics Inc. Same sector
via Lonnel Coats

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $2,773,048; 9 purchases by 3 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 6, 2026	Michael Exton Director, Officer (Chief Executive Officer)	Open-market purchase	+30,064	$1.66	$49,999
Jun 3, 2026	Judith L. Swain Director	Option exercise	+89,312	—	—
Jun 3, 2026	Diane E. Sullivan Director	Option exercise	+89,312	—	—
Jun 3, 2026	Christopher J. Sobecki Director	Option exercise	+89,312	—	—
Jun 3, 2026	Ivan Cheung Director	Option exercise	+89,312	—	—
Jun 3, 2026	Sam L. Barker Director	Option exercise	+89,312	—	—
Jun 3, 2026	Philippe Amouyal Director	Option exercise	+89,312	—	—
Jun 3, 2026	Raymond Debbane Director	Option exercise	+89,312	—	—
Apr 30, 2026	Participations S.a R.l. Artal Director, 10% owner	Option exercise	+20,421,735	—	—
Feb 28, 2026	McDermott Wendy Officer (SVP, Human Resources)	Option exercise	+27,697	—	—
Feb 28, 2026	Martens Rachel Yap Officer (SVP, Partnerships & Corp Strat)	Option exercise	+67,090	—	—
Feb 28, 2026	Granowitz Craig B Officer (SVP, Chief Medical Officer)	Option exercise	+35,790	—	—
Feb 28, 2026	Gopinathan Suma Officer (SVP, Discovery)	Option exercise	+14,000	—	—
Feb 28, 2026	DeFrancesco Lisa Officer (SVP, IR and Corp Comm)	Option exercise	+24,674	—	—
Feb 28, 2026	Crum Brian T Officer (SVP, General Counsel & Secr.)	Option exercise	+33,457	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Lexicon Pharmaceuticals Inc.

Who is the CEO of Lexicon Pharmaceuticals Inc.?

Michael Exton has been Lexicon Pharmaceuticals Inc.'s Chief Executive Officer since July 2024.

How many directors are on Lexicon Pharmaceuticals Inc.'s board?

Lexicon Pharmaceuticals Inc.'s board has 17 directors: Administratiekantoor Westend Stichting, Alan S. Nies, Amaury Wittouck, Christopher J. Sobecki, Diane E. Sullivan, Frank Palantoni, International S.c.a. Artal, Ivan Cheung, Judith L. Swain, Lonnel Coats and 7 others.

Are Lexicon Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Lexicon Pharmaceuticals Inc. insiders bought $2.8 million of shares in 9 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Lexicon Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="lexicon-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.